Search Results for: 19

ROCKVILLE, Md., July 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has closed the public offering of 15.3 million shares of common stock, including the fully exercised over-allotment option by the underwriters covering 2.0 million […]

ROCKVILLE, Md., July 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has priced an underwritten public offering of 13.3 million shares of common stock at a price of $3.00 per share, for expected gross proceeds

ROCKVILLE, Md., July 15, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by

— Study to Evaluate Effect of SYN-010 in Reducing Methane Production in the Gut — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., June 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the

— Study to Evaluate SYN-004’s Antibiotic-Degrading Effect in the Gut in the Presence of Esomeprazole — ROCKVILLE, Md., June 12, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, dosed the first participant in a second Phase 2a clinical trial of

— Successful Clinical Development Would Enable Company’s Microbiome-Protecting Therapeutics to Cover all Three Beta-Lactam Antibiotic Classes — — Webcast Details Below for Microbiome Analyst & Investor Meeting Live Today at 9:00 a.m. EDT — ROCKVILLE, Md., June 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), this week presented initial data that support the

— GI Clinician and Scientist Most Recently Served in Leadership Positions at Quintiles and the U.S. Food & Drug Administration (FDA) — ROCKVILLE, Md., June 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Klaus Gottlieb, MD, FACG, has

— Leading Clinicians to Discuss Novel Approaches to Treating IBS-C and Preventing C. difficile — — Webcast Scheduled at 9:00 a.m. EDT on Wednesday, June 3, 2015 — ROCKVILLE, Md., June 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific

— Company’s Program for Prevention of C. difficile Infection in Phase 2a Clinical Trial and on Target for Phase 2b Clinical Trial Initiation in 2H 2015 — ROCKVILLE, Md., May 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Company’s Irritable Bowel Syndrome with Constipation (IBS-C) Program to Reduce the Impact of Methane Gas in the Gut on Target to Initiate Phase 2 Clinical Trial in 2Q 2015 — ROCKVILLE, Md., May 18, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome